DNA

Synthetic DNA
#Biotherapeutics #DNA #Synthetic biology #Synthetic DNA

Accelerating biotherapy and personalised medicine with long DNA

Listen to this article on the DDW Podcast: Matt Hill, Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development. With advanced technology and a growing understanding of the underlying biology, biotherapy development has evolved. Since 2010, investments in the… Read More

#Exclusive Content

Touchlight exterior view London
#Biopharmaceuticals #DNA #Genetics #Plasmid DNA

New London facility exceeds global plasmid DNA demand 

Touchlight, a company providing DNA services and manufacturing enzymes, has completed the redevelopment and expansion of its UK manufacturing facility in London, UK.   The expanded facility’s manufacturing capacity has tripled and is now capable of producing more than 8kg a year. This exceeds the current, but growing,… Read More

#News

#DNA #Drug discovery #INTEGRA #Laboratory #PCR

eBook: Learn how to become a PCR pro

The term ‘PCR’ has been on everybody’s lips since the outbreak of the Covid-19 pandemic, but only laboratory professionals know how difficult it can be to achieve success with this well-established technique. If your PCR reactions are driving you to despair, look no further than INTEGRA’s comprehensive… Read More

#News

#DNA #Drug discovery #INTEGRA #Laboratory #PCR

How to become a PCR pro

The term ‘PCR’ has been on everybody’s lips since the outbreak of the Covid-19 pandemic, but only laboratory professionals know how difficult it can be to achieve success with this well-established technique. If your PCR reactions are driving you to despair, look no further than INTEGRA’s comprehensive eBook! Learn more… Read More

#Resources

Human breast cancer cells stained for DNA
#Cancer research #Collaboration #DNA #NeoPhore #Oncology #Partnership #The Institute of Cancer Research

Immuno-oncology collaboration to develop new type of cancer drug

Scientists at The Institute of Cancer Research, London, are teaming up with small molecule neoantigen immuno-oncology company NeoPhore to develop new potential cancer drugs. Under a new strategic research collaboration, an ICR team led by Professor Chris Lord will investigate the effect of NeoPhore’s inhibitors on tumours in the laboratory. Read More

#Business & Investment #News

Damaged DNA
#Biosensors #Cancer research #DNA #Korea #Oncology

Novel biosensor could help optimise cancer treatment

Scientists from Korea have developed a new biosensor that uses fluorescence resonance energy transfer (FRET) to detect DNA double-strand breaks in living specimens in real time. This biosensor has the potential to aid the development of new treatments for DNA damage-related diseases by revealing how our… Read More

#Cancer Research #News

#3D modelling #Biochemistry #CRISPR #DNA #Drug discovery #Gene editing #Genomics #Mass spectrometry / NMR #Screening

Podcast: Mass spectrometry and CRISPR

This is the latest episode of the free DDW podcast, “Mass spectrometry and CRISPR are pillars of drug discovery”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “How ASMS offers more than seeing what sticks” and “… Read More

#News

Protein degradation
#Collaboration #DNA #Kymera Therapeutics #Library screening #Partnership #Protein chemistry / Proteomics #X-Chem

X-Chem and Kymera expand partnership to 12 targets

X-Chem and Kymera Therapeutics have expanded their collaboration, which will now comprise 12 targets and grants Kymera exclusive rights to compounds discovered within the collaboration.   With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library (DEL)-based screening services to Kymera – using its DEL platform to… Read More

#Business & Investment #News

#DNA #Financing #Funding #Investment #Synthetic biology

$24 million funding to accelerate synthetic biology research

Evonetix has completed a $24 million financing round, extending its total series B funding to over $54 million.   The fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also participating in the round.  The investment will enable the continued development… Read More

#Business & Investment #News

#AI #Biopharma #Biopharmaceuticals #Comment #DNA #Lab automation #SLAS2022 #Synthetic biology

Podcast: The impact of synthetic biology and collaboration in pharma

This is the latest episode of the free DDW podcast. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Why synthetic biology is the next big thing for biopharma” and “Collaborative spirit helps drive innovation”. ‘Can synthetic biology save… Read More

#News

#Assays #Biotechnology #DNA #Next generation sequencing #Research

Key acquisition for next generation sequencing research assays

Integrated DNA Technologies has purchased next generation sequencing (NGS) research assays from Invitae Corporation under the trademarked name Archer.   The integration of IDT’s portfolio with the acquired NGS research assays—which have been foundational in researching novel cancer fusions—will empower labs with a solution to uncover biomarkers and… Read More

#News

#AI / data analytics / healthtech / informatics #Computer modelling #DEL #DNA #Drug discovery #Library screening #Target identification

New trends in DNA-encoded library screening

Matthew Clark, CEO of X-Chem, looks at what the future could hold for DNA-encoded library (DEL) technology. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Most major pharma companies operate DEL… Read More

#Exclusive Content #Trends & Analysis

CRISPR gene editing
#Cell and gene therapy #CRISPR #DNA #Gene editing #Genetics / genomics

Delivering on the promise of gene editing

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Gene editing tools such as zinc finger nucleases, transcription activator-like effector nucleases (TALEN) and clustered regularly interspaced… Read More

#Exclusive Content

#DNA #Gene mutation #Gene sequencing #Paediatrics #Rare disease

Researchers investigate genetic variants of paediatric diseases 

PacBio, developer of sequencing solutions, has announced its HiFi sequencing technology will be used in a pilot project for the Children’s Rare Disease Cohorts Initiative (CRDC) at Boston Children’s Hospital.   Boston Children’s Hospital researchers will use HiFi whole-genome sequencing (HiFi WGS) for the purpose of investigating genetic… Read More

#News

#Biopharma #Biopharmaceuticals #DNA #Synthetic biology

Why synthetic biology is the next big thing for biopharma 

Listen to this article on the DDW Podcast: ‘Can synthetic biology save us?’ and ‘synthetic biology can benefit us all’, are just some of the headlines this emerging scientific field has recently elicited. Lu Rahman speaks to Dr Emily Leproust, Founder and CEO of Twist Biopharma, about the potential that synthetic biology holds within… Read More

#Exclusive Content

Genetic engineering
#Bowel cancer #Cancer #Cancer research #DNA #DNA mutations #Epigenetics #Oncology #Treatment outcomes

Epigenetics vital in predicting cancer drug outcomes 

Cancers can evolve to become more aggressive without relying only on DNA mutations, two major studies have revealed.  The research characterises an extra level of control of cancer gene activity within tumours, which the researchers describe as cancer’s ‘dark matter’.  The two studies showed how… Read More

#Cancer Research #News